This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, 40 FR 43745–46, all applicants for registration to import a basic class of any controlled substances in schedules I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.

Dated: March 7, 2013.

Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2013–05794 Filed 3–12–13; 8:45 am]
BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE
Drug Enforcement Administration

Importer of Controlled Substances, Notice of Registration: Hospira Inc.

By Notice dated December 14, 2012, and published in the Federal Register on December 21, 2012, 77 FR 75670, Hospira Inc., 1776 North Centennial Drive, McPherson, Kansas 67460–1247, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of Remifentanil (9739), a basic class of controlled substance listed in schedule II.

The company plans to import Remifentanil for use in dosage form manufacturing.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a), and determined that the registration of Hospira Inc. to import the basic class of controlled substance is consistent with the public interest, and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated Hospira Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history.

Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 U.S.C. 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic class of controlled substance listed.

Dated: March 7, 2013.

Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2013–05794 Filed 3–12–13; 8:45 am]
BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE
Drug Enforcement Administration

Manufacturer of Controlled Substances, Notice of Registration; Johnson Matthey Inc., Pharmaceuticals Materials

By Notice dated November 1, 2012, and published in the Federal Register on November 9, 2012, 77 FR 67397, Johnson Matthey Inc., Pharmaceuticals Materials, 900 River Road, Conshohocken, Pennsylvania 19428, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

<table>
<thead>
<tr>
<th>Drug</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gamma Hydroxybutyric Acid</td>
<td>I</td>
</tr>
<tr>
<td>Amphetamine (1100)</td>
<td>II</td>
</tr>
<tr>
<td>Methylphenidate (1724)</td>
<td>II</td>
</tr>
<tr>
<td>Codeine (9050)</td>
<td>II</td>
</tr>
<tr>
<td>Oxycodone (9143)</td>
<td>II</td>
</tr>
<tr>
<td>Diphenoxylate (9170)</td>
<td>II</td>
</tr>
<tr>
<td>Hydrocodone (9193)</td>
<td>II</td>
</tr>
<tr>
<td>Meperidine (9230)</td>
<td>II</td>
</tr>
<tr>
<td>Methadone (9250)</td>
<td>II</td>
</tr>
<tr>
<td>Methadone Intermediate (9224)</td>
<td>II</td>
</tr>
<tr>
<td>Morphine (9300)</td>
<td>II</td>
</tr>
<tr>
<td>Thebaine (9333)</td>
<td>II</td>
</tr>
</tbody>
</table>

The company plans to manufacture the listed controlled substances in bulk for distribution and sale to its customers.

The Thebaine (9333) will also be used to manufacture other controlled substances for sale in bulk to its customers.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Johnson Matthey Inc., Pharmaceuticals Materials to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Johnson Matthey Inc., Pharmaceuticals Materials to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history.

Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed.

Dated: February 27, 2013.

Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2013–05799 Filed 3–12–13; 8:45 am]
BILLING CODE 4410–09–P

DEPARTMENT OF LABOR
Office of the Secretary

Agency Information Collection Activities; Submission for OMB Review; Comment Request; Job Clubs Study

ACTION: Notice; correction.

SUMMARY: The Department of Labor published a document in the Federal Register of February 26, 2013, concerning request for comments on site visits to job clubs. The document contained incorrect dates.

FOR FURTHER INFORMATION CONTACT: Contact Ben Seigel by telephone at 202–693–6032 (this is not a toll-free number) or by email at CFBNP@dom.gov.

Correction

In the Federal Register of February 26, 2013, in FR Doc. 2013–04391, on page 13086, in the second column, correct the DATES caption to read:

DATES: Written comments must be submitted to the office listed in the addressee section on or before April 27, 2013.

Signed at Washington, DC, this 5th day of March, 2013.

Irasema Garza,
Acting Assistant Secretary for Policy, U.S. Department of Labor.